ArriVent BioPharma, Inc. (AVBP): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$180.56M

Year ended 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$180.56M	n/a	2026-03-05, From 2025-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
ArriVent BioPharma, Inc. (AVBP)	2025-12-31	-$180.56M	n/a
Rocket Pharmaceuticals, Inc. (RCKT)	2025-12-31	-$222.85M	n/m
Liquidia Corp (LQDA)	2025-12-31	-$49.85M	n/m
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	-$178.08M	n/m
Prothena Corp Public Ltd Co (PRTA)	2025-12-31	-$213.75M	n/m
Lyell Immunopharma, Inc. (LYEL)	2025-12-31	-$257.87M	n/m
Omeros Corp (OMER)	2025-12-31	-$121.80M	n/m
Atea Pharmaceuticals, Inc. (AVIR)	2025-12-31	-$180.47M	n/m
Upstream Bio, Inc. (UPB)	2025-12-31	-$160.17M	n/m

Compare AVBP, RCKT, LQDA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗